SEC Form 4 · accession 0001193125-26-349960
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tan Aik Na
Director
Period of report
Aug 11, 2026
Accepted (ET)
Aug 13, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 11, 2026 | S | 432 | $6.01 | D | 24,968 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On August 11, 2026, the reporting person sold 432 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan.
Remarks
On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney